Orchestra BioMed Holdings, Inc. (OBIO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Orchestra BioMed Holdings, Inc. (OBIO) closed at USD 5.64 on 2026-10-14, a change of +48.8 % over the past year, with a market capitalization of USD 345M.

Orchestra BioMed Holdings, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Orchestra BioMed Holdings, Inc. key figures

Previous close

USD 5.64 (2026-10-14)

1-year change

+48.8 %

Market cap

USD 345M

Enterprise value

USD 315.9M

P/E ratio (trailing)

-6.75

P/E ratio (forward)

-3.80

EPS (trailing)

-0.85

EPS (forward)

-1.51

PEG ratio

n/a

Price to book

17.88

Revenue growth

-89.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.00

Employees

86

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Orchestra BioMed Holdings, Inc. and compare it with other stocks.